1.Single-nucleotide polymorphisms in DNA repair genes APE1 and XRCC1 and suscep-tibility to hepatocellular carcinoma and their correlation with sensitivity of platinum chemotherapy in HCC
Zhuangwei FANG ; Zhu LIANG ; Ning WU ; Chun QIU ; Fuhuang LIN ; Bo YUAN ; Yonghong PENG ; Yong FU ; Weiping ZHOU ; Kailun ZHOU ; Xianhe XIE
Military Medical Sciences 2014;(1):48-52
Objective To investigate the relationship between APE1, XRCC1 gene polymorphisms and hepatocellular carcinoma(HCC) susceptibility and to explore the correlation of APE1, XRCC1 gene polymorphisms with the sensitivity to platinum-based drugs .Methods Seventy-eight HCC patients and 80 controls were selected .By PCR and RFLP , the single nucleotide polymorphism of APE1 Asp148Glu and XRCC1 Arg194Trp genes and the susceptibility of HCC or platinum drug sensitivity were analyzed.Results The Glu/Glu genotype of APE1 could increase in the risk of HCC by 7.21 times (95%CI:1.325-29.109) (P<0.05).APE1 and XRCC1 gene polymorphisms could also affect the platinum drug resistance of HCC patients.Conclusion APE1 Asp148Glu is correlated with the susceptibility to HCC .APE1 and XRCC1 genes can be considered a target for therapy to improve the sensitivity of HCC platinum drugs .
2.Efficacy and safety of capecitabine in treatment of colorectal cancer
Zhuangwei FANG ; Bo YUAN ; Ping HUANG ; Weiping ZHOU ; Guohao CAI ; Yong FU ; Qinghua WANG ; Youqun HUANG ; Kejian ZOU ; Renfeng MULIN ; LI YE
The Journal of Practical Medicine 2017;33(19):3287-3290
Objective To investigate the efficacy and safety of capecitabine in the treatment of colorectal cancer. Methods Totally 160 elderly patients with stageⅣcolorectal cancer were enrolled in this study. After first-line combined chemotherapy,80 patients were treated with capecitabine monotherapy(maintenance group)and another 80 cases were not(control group). The survival rate was analyzed by Kaplan-Meier curve and the efficiency and incidence of adverse events were compared. Results (1) The Kaplan-Meier curve suggested that the difference between two groups was statistically significant(P<0.05).(2)The response rate of maintenance group was significantly higher than that of control group (P < 0.05). (3)The incidence of adverse events during capecitabine monotherapy was lower than that during combined chemotherapy(P < 0.05).(4)The incidence of adverse reactions during capecitabine monotherapy was similar to that of control group(P > 0.05). Conclusion Capecitabine monotherapy in patients with stage Ⅳ colorectal cancer after combined chemotherapy has a longer median PFS than those without maintenance but similar adverse reactions ,which was worthy of clinical promotion.
Result Analysis
Print
Save
E-mail